Intravenous Immunoglobulin Market Growth Opportunities, Share And Forecast To 2033

The Business Research Company recently released a comprehensive report on the Global Intravenous Immunoglobulin Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

According to The Business Research Company's, The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $13.82 billion in 2023 to $14.84 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders , management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $20.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches. Major trends in the forecast period include primary immunodeficiency disorders (pidd) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Market Drivers and Trends:

The increasing prevalence of rheumatoid arthritis is expected to propel the growth of the intravenous immunoglobulin (IVIG) market going forward. Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation, pain, swelling, and stiffness in the joints. It is a long-term condition that can lead to joint damage and disability if left untreated. IVIG is a blood product that contains antibodies from healthy donors. These antibodies can help to block the inflammatory process that leads to joint damage in RA. For instance, in June 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 456,000 Australians (1.9%) will have rheumatoid arthritis. RA accounted for 2.0% of the total disease burden and 16% of the total burden of disease due to musculoskeletal conditions in 2022. Furthermore, in July 2022, according to the National Rheumatoid Arthritis Society (NRAS), a UK-based non-profit organization, it was estimated that more than 450,000 people in the UK have rheumatoid arthritis. The most common age for people to develop RA is between 40 and 60, or a bit older for men. Therefore, the increasing prevalence of rheumatoid arthritis is driving the growth of the intravenous immunoglobulin (IVIG) market.

Product innovation is a key trend gaining popularity in the intravenous immunoglobulin market. Major companies in the market are focusing on innovating new products such as human plasma-derived intravenous immunoglobulin (IVIg) for the treatment of rare diseases and sustaining their position in the market. For instance, in June 2021, Octapharma, a Swiss pharmaceutical company, announced that its new product 'Octagam 10%', a human plasma-derived intravenous immunoglobulin (IVIg) was granted approval by the European Union (EU) as immunotherapy for adults with dermatomyositis, and national approval by Germany for the same indication. Octagam 10% is the first therapy to be approved for dermatomyositis in the EU and indicated for adults with active dermatomyositis treated with immunosuppressive drugs. This innovative product will help improve the lives of people with dermatomyositis, which is a rare, idiopathic autoimmune disorder.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., Emergent BioSolutions Inc., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Intravenous Immunoglobulin Market 2024 Key Insights:

• The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $20.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%.
• Rising Geriatric Population Fuels Growth In The Intravenous Immunoglobulin Market
• Innovative Human Plasma-Derived Ivig Products Drive Advancements In The Intravenous Immunoglobulin Market
• North America was the largest region in the intravenous immunoglobulin market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=8538&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.